Wim Souverijns Sells 20,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $39.31, for a total transaction of $786,200.00. Following the sale, the insider owned 45,111 shares in the company, valued at $1,773,313.41. The trade was a 30.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Wim Souverijns also recently made the following trade(s):

• On Tuesday, September 15th, Wim Souverijns sold 6,090 shares of Pharvaris stock. The stock was sold at an average price of $38.99, for a total transaction of $237,449.10.

Pharvaris Trading Down 1.9%

Shares of PHVS stock traded down $0.73 on Wednesday, reaching $37.33. 426,621 shares of the stock were exchanged, compared to its average volume of 403,904. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -12.24 and a beta of -2.33. The business’s 50 day moving average price is $35.27 and its 200 day moving average price is $31.56.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities research analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently modified their holdings of PHVS. Alyeska Investment Group L.P. lifted its holdings in shares of Pharvaris by 225.5% during the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after buying an additional 281,829 shares during the last quarter. BlackRock Inc. bought a new stake in Pharvaris in the 2nd quarter valued at $26,677,000. Seven Fleet Capital Management LP grew its position in Pharvaris by 472.3% in the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock worth $8,947,000 after purchasing an additional 261,355 shares during the last quarter. PSP Research LLC acquired a new stake in Pharvaris in the 4th quarter worth $569,000. Finally, DV Trading LLC bought a new position in shares of Pharvaris during the 1st quarter worth about $4,067,000.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Phase III results for once-daily extended-release deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks. The data support Pharvaris’ plans for regulatory submissions in 2027 and strengthen the commercial outlook for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst sentiment remains favorable. The reported consensus price target increased 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. MarketBeat data shows a “Moderate Buy” consensus with an average target near $59.87. Pharvaris consensus price target raised
• Positive Sentiment: Institutional interest has expanded, with BlackRock establishing a position and Alyeska Investment Group and Seven Fleet Capital substantially increasing their holdings. Such buying can support investor confidence in PHVS.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript headline does not identify a new announcement. Morgan Stanley Global Healthcare Conference transcript
• Negative Sentiment: Insiders have been selling shares. CEO Berndt Modig sold 2,291 shares worth approximately $90,265, while President Peng Lu sold 15,000 shares and Anne Lesage sold 30,000 shares worth about $1.15 million. Lu’s transaction was intended to cover tax withholding on vested equity, somewhat reducing its negative significance, but the overall selling may weigh on sentiment. Pharvaris insider selling report
• Negative Sentiment: Pharvaris remains unprofitable and previously reported quarterly EPS of negative $0.81, below the consensus estimate of negative $0.75. Analysts expect a full-year loss of approximately $3.12 per share, underscoring continued development and financing risk.

Wall Street Analysts Forecast Growth

PHVS has been the topic of several research reports. Royal Bank Of Canada increased their target price on Pharvaris from $52.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price objective on Pharvaris in a report on Wednesday, September 9th. Wells Fargo & Company lifted their price objective on Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. UBS Group set a $79.00 target price on Pharvaris in a report on Wednesday, September 9th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, September 8th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.